# Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

> **NCT06859099** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Sanofi** · enrollment: 300 (estimated)

## Conditions studied

- Polyneuropathy, Inflammatory Demyelinating, Chronic

## Interventions

- **DRUG:** Riliprubart Prefilled Pen (PFP)

## Key facts

- **NCT ID:** NCT06859099
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-01
- **Primary completion:** 2029-10-03
- **Final completion:** 2029-10-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859099, "Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06859099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*